AxoGen Inc. (AXGN) Given Buy Rating at JMP Securities
AXGN has been the subject of a number of other research reports. Lake Street Capital downgraded AxoGen from a buy rating to a hold rating and set a $9.00 price objective for the company. in a research report on Thursday, November 3rd. Wedbush reaffirmed an outperform rating and issued a $10.00 price objective (up previously from $9.00) on shares of AxoGen in a research report on Thursday, August 4th.
AxoGen (NASDAQ:AXGN) traded up 2.89% during midday trading on Tuesday, reaching $8.90. The company’s stock had a trading volume of 72,846 shares. The company’s market capitalization is $292.79 million. The company has a 50 day moving average of $8.65 and a 200-day moving average of $7.62. AxoGen has a 1-year low of $4.52 and a 1-year high of $9.88.
AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.08) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.08). AxoGen had a negative return on equity of 292.94% and a negative net margin of 33.02%. Equities research analysts anticipate that AxoGen will post ($0.38) earnings per share for the current fiscal year.
In other news, Director Amy Mcbride Wendell purchased 13,333 shares of the stock in a transaction on Friday, October 7th. The stock was purchased at an average price of $7.50 per share, with a total value of $99,997.50. Following the completion of the transaction, the director now owns 13,333 shares in the company, valued at $99,997.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Karen L. Zaderej purchased 10,000 shares of the stock in a transaction on Friday, October 7th. The shares were purchased at an average cost of $7.50 per share, with a total value of $75,000.00. Following the transaction, the chief executive officer now owns 242,147 shares of the company’s stock, valued at approximately $1,816,102.50. The disclosure for this purchase can be found here. Company insiders own 9.33% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Prudential Financial Inc. bought a new position in shares of AxoGen during the third quarter worth approximately $109,000. Susquehanna International Group LLP bought a new position in shares of AxoGen during the third quarter worth approximately $112,000. BlackRock Advisors LLC boosted its position in shares of AxoGen by 57.4% in the third quarter. BlackRock Advisors LLC now owns 13,379 shares of the company’s stock worth $121,000 after buying an additional 4,878 shares in the last quarter. Nationwide Fund Advisors bought a new position in shares of AxoGen during the second quarter worth approximately $105,000. Finally, TFS Capital LLC bought a new position in shares of AxoGen during the second quarter worth approximately $113,000. Institutional investors own 54.43% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2016/11/23/axogen-inc-axgn-given-buy-rating-at-jmp-securities.html.
Receive News & Stock Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related stocks with our FREE daily email newsletter.